methods: Adult patients were selected from the HealthCore Integrated Research DatabaseSM. High-risk patients who achieved LDL-P <1000 between 1/1/2006 and 9/30/2012 were placed into the LDL-P cohort with the index date being the earliest observed LDL-P target. Patients without LDL-P measurements, but who achieved LDL-C <100, were placed into the LDL-C cohort. Baseline patient characteristics were assessed 6 months pre-index and patients were followed for 12-36 months post-index. Propensity score matching was used to balance pre-index demographic and comorbidity differences between cohorts while leaving treatment patterns intact.
results: Matched LDL-P and LDL-C patients were balanced with respect to demographics and comorbidities. LDL-P patients were more likely to receive higher potency statins at baseline. During 12-36 months follow-up, LDL-P patients had fewer CV events versus LDL-C patients (36 month HR= 0.75; 95% CI 0.58-0.97).
conclusion: In this real-world sample of commercially insured patients, results suggest that patients achieving LDL-P <1000 received more aggressive lipid-lowering treatment than patients achieving LDL-C <100, and that these treatment differences are associated with a reduction in CV event rates over 12-36 months follow-up. 
